Meropenem Dosing in Sepsis
For adults with sepsis, administer meropenem 1 gram IV every 8 hours as a standard dose, with consideration for extended or continuous infusion to optimize pharmacokinetic/pharmacodynamic targets, particularly in critically ill patients or those with augmented renal clearance.
Adult Dosing
Standard Dosing
The FDA-approved dosing for serious infections is 1 gram IV every 8 hours for intra-abdominal infections and 500 mg every 8 hours for complicated skin and skin structure infections 1. However, for sepsis specifically, the 1 gram dose is more appropriate given the severity of illness. When treating Pseudomonas aeruginosa, increase to 1 gram every 8 hours regardless of infection site 1.
Administration Method
Extended or continuous infusion is superior to standard 30-minute infusions in septic patients. The Surviving Sepsis Campaign guidelines support extended infusion of beta-lactams to increase time above MIC (T>MIC), particularly for resistant organisms and critically ill patients 2. Recent high-quality evidence shows:
- High-dose meropenem (6 g/day via intermittent infusion) was associated with significantly lower 90-day mortality (31.5% vs 40.9%, p<0.001) compared to standard 3 g/day in critically ill patients 3
- Continuous infusion achieves target concentrations in 97% of patients versus 64% with extended intermittent infusion 4
- French guidelines recommend optimized dosing strategies with extended/continuous infusion for critically ill septic patients 5
Practical approach:
- Administer initial dose as rapid infusion over 15-30 minutes to achieve therapeutic levels quickly
- Subsequent doses: extend infusion to 3 hours OR use continuous infusion (particularly for MIC ≥2 mg/L pathogens)
- For continuous infusion: 3-6 g/day depending on renal function 4, 6
Renal Impairment Adjustments
Dose reduction is mandatory when creatinine clearance falls below 50 mL/min 1:
| CrCl (mL/min) | Dose | Interval |
|---|---|---|
| >50 | 1 gram | Every 8 hours |
| 26-50 | 1 gram | Every 12 hours |
| 10-25 | 500 mg | Every 12 hours |
| <10 | 500 mg | Every 24 hours |
Critical caveat: Patients with augmented renal clearance (ARC) - common in early sepsis - require HIGHER doses. When eGFR >160 mL/min/1.73m², standard dosing results in subtherapeutic levels in 80% of patients 7, 8. Consider:
Continuous Renal Replacement Therapy (CRRT)
CRRT increases meropenem clearance by 2.1-fold compared to renal impairment alone 10. Recommended dosing:
Pediatric Dosing
Children ≥3 Months
Dose based on infection type and weight 1:
| Indication | Dose | Maximum | Interval |
|---|---|---|---|
| Complicated skin/soft tissue | 10 mg/kg | 500 mg | Every 8 hours |
| Intra-abdominal infection | 20 mg/kg | 1 gram | Every 8 hours |
| Meningitis | 40 mg/kg | 2 grams | Every 8 hours |
For P. aeruginosa skin infections: Use 20 mg/kg (max 1 gram) every 8 hours 1.
Administration: 15-30 minute infusion for standard doses; 3-5 minute bolus acceptable for doses ≤1 gram in adults (limited pediatric bolus safety data for 40 mg/kg doses) 1.
Infants <3 Months (Complicated Intra-abdominal Infections Only)
Dosing based on gestational age (GA) and postnatal age (PNA) 1:
| GA and PNA | Dose | Interval |
|---|---|---|
| <32 weeks GA, PNA <2 weeks | 20 mg/kg | Every 12 hours |
| <32 weeks GA, PNA ≥2 weeks | 20 mg/kg | Every 8 hours |
| ≥32 weeks GA, PNA <2 weeks | 20 mg/kg | Every 8 hours |
| ≥32 weeks GA, PNA ≥2 weeks | 30 mg/kg | Every 8 hours |
Administer as 30-minute infusion 1.
Pediatric Considerations
- No established dosing for pediatric renal impairment - use clinical judgment and consider therapeutic drug monitoring 1
- Augmented renal clearance is common in pediatric sepsis - approximately 49% of children with sepsis develop increased eGFR by day 2, with 17% meeting ARC criteria 7, 11
- Standard doses may be inadequate for P. aeruginosa (MIC 2 mg/L) in children with ARC - 80% fail to achieve 80% T>MIC 7
Key Clinical Pitfalls
Underestimating ARC: Early sepsis often causes increased renal clearance, not decreased. Monitor for clinical non-response despite "adequate" dosing 7, 8, 11.
Neurotoxicity risk: Meropenem has relatively low seizure risk (relative activity 16 vs penicillin G = 100), but toxicity occurs when trough levels exceed 64 mg/L 5. Risk increases with:
- Renal impairment
- CNS pathology
- Doses exceeding 70 mg/kg/day 4
Valproic acid interaction: Meropenem reduces valproic acid levels by 50-100%, increasing seizure risk. Generally avoid this combination - use alternative antibiotics in patients on valproic acid for seizure control 1.
Therapeutic drug monitoring: While not routinely available for meropenem, consider TDM in critically ill patients, those with ARC, or treatment failures to optimize dosing 2, 5.